Evidence for multiple B- and T-cell epitopes in Plasmodium falciparum liver-stage antigen 3 Toure Balde, A. Perlaza, B.L. Sauzet, J.P. Ndiaye, M. Aribot, G. Tall, A. /Sokhna, Cheikh Rogier, C. Corradin, G. Roussilhon, C. Druilhe, P. Liver-stage antigen 3 (LSA-3) is a new vaccine candidate that can induce protection against Plasmodium falciparum sporozoite challenge. Using a series of long synthetic peptides (LSP) encompassing most of the 210-kDa LSA-3 protein, a study of the antigenicity of this protein was carried out in 203 inhabitants from the villages of Dielmo (n=143) and Ndiop (n=60) in Senegal (the level of malaria transmission differs in these two villages). Lymphocyte responses to each individual LSA-3 peptide were recorded, some at high prevalences (up to 43%). Antibodies were also detected to each of the 20 peptides, many at high prevalence (up to 84% of responders), and were directed to both nonrepeat and repeat regions. Immune responses to LSA-3 were detectable even in individuals of less than 5 years of age and increased with age and hence exposure to malaria, although they were not directly related to the level of malaria transmission. Thus, several valuable T- and B-cell epitopes were characterized all along the LSA-3 protein, supporting the antigenicity of this P. falciparum vaccine candidate. Finally, antibodies specific for peptide LSP10 located in a nonrepeat region of LSA-3 were found significantly associated with a lower risk of malaria attack over 1 year of daily clinical follow-up in children between the ages of 7 and 15 years, but not in older individuals. 2009 text https://www.documentation.ird.fr/hor/PAR00003353 PAR00003353 Toure Balde A., Perlaza B.L., Sauzet J.P., Ndiaye M., Aribot G., Tall A., Sokhna Cheikh, Rogier C., Corradin G., Roussilhon C., Druilhe P.. Evidence for multiple B- and T-cell epitopes in Plasmodium falciparum liver-stage antigen 3. 2009, 77 (3), 1189-1196 EN